Probably coming soon to a TV near you: Ads for a $56,000 Alzheimer’s drug that likely won’t work
Against the recommendation of an independent advisory committee, the Food and Drug Administration approved a new therapy for Alzheimer’s disease earlier this month. The drug, aducanumab, will be sold by Massachusetts-based company Biogen under the name Aduhelm. The drug will be sold at an expected annual cost of $56,000—Per. Patient.